Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Sonora Investment Management Group LLC

Sonora Investment Management Group LLC cut its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.1% in the fourth quarter, HoldingsChannel reports. The fund owned 86,931 shares of the biopharmaceutical company’s stock after selling 953 shares during the quarter. Sonora Investment Management Group LLC’s holdings in Intra-Cellular Therapies were worth $7,260,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in shares of Intra-Cellular Therapies in the fourth quarter worth approximately $205,000. KBC Group NV boosted its stake in shares of Intra-Cellular Therapies by 31.8% during the 4th quarter. KBC Group NV now owns 3,774 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 910 shares during the period. SG Americas Securities LLC grew its holdings in shares of Intra-Cellular Therapies by 204.4% during the 4th quarter. SG Americas Securities LLC now owns 12,917 shares of the biopharmaceutical company’s stock valued at $1,079,000 after acquiring an additional 8,673 shares in the last quarter. Cetera Trust Company N.A increased its stake in shares of Intra-Cellular Therapies by 17.3% in the fourth quarter. Cetera Trust Company N.A now owns 2,955 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 435 shares during the last quarter. Finally, Barlow Wealth Partners Inc. purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth $184,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI opened at $127.00 on Friday. The company’s fifty day moving average is $95.79 and its two-hundred day moving average is $83.81. Intra-Cellular Therapies, Inc. has a 52-week low of $62.78 and a 52-week high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. The business’s revenue for the quarter was up 39.0% on a year-over-year basis. Research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Insider Transactions at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. 2.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ITCI has been the topic of several research reports. Needham & Company LLC reaffirmed a “hold” rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Piper Sandler restated a “neutral” rating and set a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Morgan Stanley upped their price objective on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $102.15.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.